Galectin Therapeutics Inc. (GALT)

Oncology Corporate Profile

Stock Performance

1.9100
0.0300

3 Month Stock History Chart

HQ Location

4960 Peachtree Industrial Boulevard, Suite 240
Norcross, GA 30071

Company Description

Galectin Therapeutics (GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. They are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. They are pursuing a clear development pathway to clinical enhancement and commercialization for their lead compounds in liver fibrosis and cancer.

Website: http://www.galectintherapeutics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
GM-MD-02 (+ ipilimumab)immunotherapyMelanomaI
GM-MD-02 (+ pembrolizumab)MelanomaI

View additional information on product candidates here »

Source: http://www.galectintherapeutics.com

Recent News Headlines

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/21/2017 06:19 am

8/18/2017 06:18 am

8/18/2017 06:18 am

8/18/2017 06:18 am

8/18/2017 06:18 am

8/14/2017 06:18 am

8/14/2017 06:18 am

8/14/2017 06:18 am

8/14/2017 06:18 am

7/25/2017 06:18 am

7/25/2017 06:18 am

7/24/2017 06:18 am

7/17/2017 06:18 am

7/7/2017 06:18 am

6/29/2017 06:18 am

6/29/2017 06:18 am

6/29/2017 06:18 am

6/23/2017 12:18 am

6/23/2017 12:18 am

6/23/2017 12:18 am

6/21/2017 06:18 am

6/13/2017 06:18 am